EA
PBYI icon

Emerald Advisers’s Puma Biotechnology PBYI Stock Holding History

Emerald Advisers’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-244,008
Closed -$11.2M – 263
2018
Q3 		$11.2M Sell
244,008
-121,779
-33% -$5.87M 0.41% 103
2018
Q2 		$21.6M Sell
365,787
-6,053
-2% -$351K 0.82% 49
2018
Q1 		$25.3M Sell
371,840
-30,828
-8% -$2.31M 1.01% 29
2017
Q4 		$39.8M Buy
402,668
+32,633
+9% +$3.65M 1.53% 14
2017
Q3 		$44.3M Buy
370,035
+52,355
+16% +$4.87M 1.8% 4
2017
Q2 		$27.8M Sell
317,680
-61,609
-16% -$3.45M 1.16% 28
2017
Q1 		$14.1M Buy
+379,289
New +$13.8M 0.58% 69
2015
Q2 		– Sell
-31,556
Closed -$6.3M – 363
2015
Q1 		$6.3M Sell
31,556
-19,165
-38% -$4.1M 0.32% 106
2014
Q4 		$9.6M Buy
50,721
+21,141
+71% +$4.69M 0.51% 68
2014
Q3 		$7.06M Buy
+29,580
New +$6.07M 0.42% 81

Other funds holding PBYI

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Emerald Advisers's PBYI Position: Q4 2018 in Review

Emerald Advisers sold out of Puma Biotechnology (PBYI) in Q4 2018, closing a stake of 244,008 shares — an estimated $11.2M sold.

Emerald Advisers first reported a position in PBYI in Q3 2014 and held it in 10 quarters. The position peaked at $44.3M in Q3 2017. 141 funds tracked by Wall St. Rank hold PBYI as of Q4 2018.

  • Emerald Advisers reported no remaining Puma Biotechnology position as of Q4 2018 after selling out during the quarter.
  • Emerald Advisers sold 244,008 Puma Biotechnology shares in Q4 2018, an estimated $11.2M.
  • Emerald Advisers first reported a position in Puma Biotechnology in Q3 2014 and held it in 10 quarters.
  • Emerald Advisers's Puma Biotechnology position peaked at $44.3M in Q3 2017.
  • 141 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2018.

Based on Emerald Advisers's 13F filing for Q4 2018, filed 30 Jan 2019.